Guerbet Past Earnings Performance

Past criteria checks 0/6

GuerbetDie Erträge des Sektors -47.5% sind im Durchschnitt pro Jahr zurückgegangen, während die Erträge des Sektors Medical Equipment growing auf 6.9% pro Jahr stiegen. Die Einnahmen sind declining mit einer durchschnittlichen Rate von 1.6% pro Jahr gesunken.

Key information

-47.5%

Earnings growth rate

-47.5%

EPS growth rate

Medical Equipment Industry Growth	21.6%
Revenue growth rate	-1.6%
Return on equity	-11.6%
Net Margin	-5.5%
Next Earnings Update	25 Sep 2024

Recent past performance updates

Recent updates

Further Upside For Guerbet SA (EPA:GBT) Shares Could Introduce Price Risks After 48% Bounce

Feb 29

Analysts Have Been Trimming Their Guerbet SA (EPA:GBT) Price Target After Its Latest Report

Mar 28

Is Guerbet (EPA:GBT) A Risky Investment?

Oct 25

The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Sep 23

Is Now The Time To Look At Buying Guerbet SA (EPA:GBT)?

May 27

We Think Guerbet (EPA:GBT) Is Taking Some Risk With Its Debt

May 04

Is Guerbet SA (EPA:GBT) A Good Fit For Your Dividend Portfolio?

Apr 05

Guerbet SA's (EPA:GBT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Mar 19

What Type Of Shareholders Make Up Guerbet SA's (EPA:GBT) Share Registry?

Mar 01

When Should You Buy Guerbet SA (EPA:GBT)?

Feb 10

How Much Did Guerbet's(EPA:GBT) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 28

Guerbet SA (EPA:GBT) Shares Could Be 25% Above Their Intrinsic Value Estimate

Jan 13

Would Guerbet SA (EPA:GBT) Be Valuable To Income Investors?

Dec 23

We Think Guerbet's (EPA:GBT) Statutory Profit Might Understate Its Earnings Potential

Dec 11

Do Its Financials Have Any Role To Play In Driving Guerbet SA's (EPA:GBT) Stock Up Recently?

Nov 27

Revenue & Expenses Breakdown
Beta

How Guerbet makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

ENXTPA:GBT Revenue, expenses and earnings (EUR Millions)
Date	Revenue	Earnings	G+A Expenses
30 Jun 23	775	-42	469
31 Mar 23	772	-42	459
31 Dec 22	769	-41	450
30 Sep 22	757	-14	439
30 Jun 22	746	13	427
31 Mar 22	741	23	418
31 Dec 21	736	33	408
30 Sep 21	724	33	405
30 Jun 21	712	33	402
31 Mar 21	715	26	411
31 Dec 20	717	18	420
30 Sep 20	751	22	429
30 Jun 20	785	26	438
31 Mar 20	802	32	452
31 Dec 19	819	37	466
30 Sep 19	813	40	468
30 Jun 19	807	43	470
31 Mar 19	801	45	463
31 Dec 18	795	47	457
30 Sep 18	793	46	456
30 Jun 18	790	46	455
31 Mar 18	800	46	453
31 Dec 17	809	46	451
30 Sep 17	807	43	448
30 Jun 17	805	40	444
31 Mar 17	791	34	438
31 Dec 16	776	29	431
30 Sep 16	709	30	398
30 Jun 16	642	31	366
31 Mar 16	566	35	319
31 Dec 15	490	39	272
30 Sep 15	462	37	256
30 Jun 15	435	35	241
31 Mar 15	422	30	235
31 Dec 14	410	26	228
30 Sep 14	405	24	226
30 Jun 14	400	23	224
31 Mar 14	395	22	223
31 Dec 13	391	20	222
30 Sep 13	394	19	221
30 Jun 13	398	17	221

Qualität der Erträge: GBT ist derzeit unrentabel.

Wachsende Gewinnspanne: GBT ist derzeit unrentabel.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Ergebnisentwicklung: GBT ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 47.5% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von GBT verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: GBT ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Medical Equipment (3.3%) erschwert.

Return on Equity

Hohe Eigenkapitalrendite: GBT hat eine negative Eigenkapitalrendite (-11.64%), da es derzeit unrentabel ist.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Guerbet Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

First half 2023 earnings released: EPS: €0.16 (vs €0.26 in 1H 2022)

Full year 2022 earnings released: €3.25 loss per share (vs €2.59 profit in FY 2021)

First half 2022 earnings released: EPS: €0.26 (vs €1.86 in 1H 2021)

Full year 2021 earnings: Revenues in line with analyst expectations

First half 2021 earnings released

Full year 2020 earnings released

Recent updates

Price target increased by 22% to €36.38

Further Upside For Guerbet SA (EPA:GBT) Shares Could Introduce Price Risks After 48% Bounce

New minor risk - Share price stability

Returns On Capital At Guerbet (EPA:GBT) Paint A Concerning Picture

Price target increased by 8.4% to €20.68

Guerbet SA (EPA:GBT) Screens Well But There Might Be A Catch

Guerbet SA, Annual General Meeting, May 24, 2024

First half 2023 earnings released: EPS: €0.16 (vs €0.26 in 1H 2022)

The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Guerbet Announces Management Appointments

Applied Radiology and Guerbet Launch 'Elucirem (Gadopiclenol) Injection

Full year 2022 earnings released: €3.25 loss per share (vs €2.59 profit in FY 2021)

Price target decreased by 14% to €20.65

Consensus EPS estimates fall by 26%

Guerbet Releases First Production Batch of Elucirem (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in Contrast-Enhanced Magnetic Resonance Imaging

Guerbet SA, Annual General Meeting, May 26, 2023

Price target decreased to €23.94

Consensus forecasts updated

Price target decreased to €26.82

First half 2022 earnings released: EPS: €0.26 (vs €1.86 in 1H 2021)

Price target decreased to €30.90

Consensus forecasts updated

Price target decreased to €32.80

Guerbet Announces U.S. Food and Drug Administration (FDA) Approval of Elucirem (Gadopiclenol)

Price target decreased to €31.55

Guerbet SA's (EPA:GBT) Intrinsic Value Is Potentially 92% Above Its Share Price

Guerbet SA Confirms Revenue Guidance for the Year of 2022

Price target decreased to €36.18

Upcoming dividend of €0.85 per share

Guerbet Sa Provides Revenue Guidance for 2022

Guerbet Announces Appointment of Charlotte Bamière, General Counsel, to the Executive Committee

Guerbet Recently Submitted New Drug Application to the U.S. Food and Drug Administration

Full year 2021 earnings: Revenues in line with analyst expectations

Analysts Have Been Trimming Their Guerbet SA (EPA:GBT) Price Target After Its Latest Report

Is Guerbet (EPA:GBT) A Risky Investment?

First half 2021 earnings released

Guerbet Provides Group Earnings Guidance for the Year 2021

The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Price target increased to €33.75

Consensus forecasts updated

Upcoming dividend of €0.70 per share

Is Now The Time To Look At Buying Guerbet SA (EPA:GBT)?

We Think Guerbet (EPA:GBT) Is Taking Some Risk With Its Debt

Is Guerbet SA (EPA:GBT) A Good Fit For Your Dividend Portfolio?

Full year 2020 earnings released

Guerbet SA's (EPA:GBT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

What Type Of Shareholders Make Up Guerbet SA's (EPA:GBT) Share Registry?

New 90-day low: €29.85

Analysts update estimates

Guerbet SA to Report Fiscal Year 2020 Results on Mar 24, 2021

When Should You Buy Guerbet SA (EPA:GBT)?

How Much Did Guerbet's(EPA:GBT) Shareholders Earn From Share Price Movements Over The Last Three Years?

Guerbet SA, Annual General Meeting, May 28, 2021

New 90-day high: €35.65

Guerbet SA (EPA:GBT) Shares Could Be 25% Above Their Intrinsic Value Estimate

Would Guerbet SA (EPA:GBT) Be Valuable To Income Investors?

New 90-day high: €33.10

We Think Guerbet's (EPA:GBT) Statutory Profit Might Understate Its Earnings Potential

Guerbet SA Receives Us Food and Drug Administration Approval for the Commercial Sale of the Optiray Imaging Bulk Package (IBP)

Do Its Financials Have Any Role To Play In Driving Guerbet SA's (EPA:GBT) Stock Up Recently?

New 90-day high: €30.00

Analysts lower EPS estimates to €1.64

Price target lowered to €31.00

First half earnings released

Analysts lower EPS estimates to €1.98

Price target lowered to €31.17

New 90-day low: €26.95

New 90-day low - €28.60

New 90-day low - €29.00

Revenue & Expenses Breakdown
Beta